Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Upfront Bevacizumab and Cetuximab Compared in mCRC

February 26th 2014

Clinical Development of Cetuximab in mCRC

February 26th 2014

Optimizing Treatment With EGFR Inhibitors in CRC

February 26th 2014

Introduction: Expanded RAS Testing in Colorectal Cancer

February 26th 2014

Dr. Fakih on Angiogenesis Versus EGFR Inhibitors in CRC

February 25th 2014

Marwan G. Fakih, MD, professor, director, Gastrointestinal Medical Oncology, City of Hope, discusses anti-angiogenesis versus anti-EGFR therapy in patients who have RAS wild-type colorectal cancer.

Dr. Bendell on using OMP-59R5 to treat Pancreatic Cancer

February 21st 2014

Johanna Bendell, MD, director of GI Cancer Research Program, associate director, Drug Development Program, Sarah Cannon Research Institute, discusses the anti-cancer stem cell antibody OMP-59R5 as a treatment option for patients with metastatic pancreatic cancer.

Genetic Analysis of Remote Population May Advance Breast Cancer Prevention and Treatment

February 18th 2014

Using blood samples collected from the Andean villagers, the laboratory at the UC Davis Genome Center uses a variety of high-throughput genetic analysis techniques to screen for genetic differences.

PARP Inhibitor BMN 673 Advances in Breast Cancer Study

February 18th 2014

As PARP inhibitors continue to emerge as a novel class of anticancer agents, BMN 673 has entered late-stage clinical development as a treatment for patients with locally advanced or metastatic breast cancer whose tumors test positive for germline BRCA1/2 mutations.

Fresh Ways of Targeting KRAS Emerge in Signaling Networks

February 14th 2014

An interview with Barry D. Nelkin, PhD, from Johns Hopkins, on his research investigating a promising new target in a KRAS-related pathway, cyclin-dependent kinase 5.

New Drug Development Needed in Pancreatic Cancer

February 11th 2014

Case Study: Treatment of Metastatic Pancreatic Cancer

February 11th 2014

Emerging Therapies and Novel Targets in Pancreatic Cancer

February 11th 2014

Novel Treatment Strategies Explored in Pancreatic Cancer

February 11th 2014

Optimizing Treatment of Advanced Pancreatic Cancer

February 11th 2014

Cost Effectiveness of Therapies in Pancreatic Cancer

February 11th 2014

Gemcitabine/Nab-Paclitaxel in Advanced Pancreatic Cancer

February 11th 2014

Introduction: FOLFIRINOX in Metastatic Pancreatic Cancer

February 11th 2014

Hopes Revived for Targeting the "Undruggable" RAS Family

February 11th 2014

The members of the RAS oncogene family are central cogs in many different cell-signaling pathways, coordinate a variety of important cellular processes, and are highly mutated in a number of different cancers, including several with extremely poor prognosis.

Final Thoughts on Improving Outcomes in NSCLC

February 7th 2014

Skeletal-Related Event Management in Lung Cancer

February 7th 2014